112 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Bristol-Myers Squibb (United States)US1 paper
- Celgene (United States)US1 paper
- Colorado State UniversityUS1 paper
- Columbia UniversityUS1 paper
- Eli Lilly (United States)US1 paper
- Genentech1 paper
- Janssen Research & Development (United States)US1 paper
- Merck & Co., Inc., Rahway, NJ, USA (United States)US1 paper
- Pfizer (United States)US1 paper
- Roche (United States)US1 paper
- Sanofi (United States)US1 paper
2 papers
stat.ME2024
ZIKQ: An innovative centile chart method for utilizing natural history data in rare disease clinical development
Tianying Wang, Wenfei Zhang, Ying Wei
Utilizing natural history data as external control plays an important role in the clinical development of rare diseases, since placebo groups in double-blind randomization trials m…
stat.AP2019★ 112 cited
Alternative Analysis Methods for Time to Event Endpoints under Non-proportional Hazards: A Comparative Analysis
Ray S. Lin, Ji Lin, Satrajit Roychoudhury +16
The log-rank test is most powerful under proportional hazards (PH). In practice, non-PH patterns are often observed in clinical trials, such as in immuno-oncology; therefore, alter…